Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Takeda Pharmaceutical Company Limited (Takeda) for access to proprietary phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics for oncology, rare diseases, neuroscience, and gastroenterology.

“Twist’s unique ability to generate robust, diverse and cutting-edge libraries through its proprietary silicon platform together with our deep insight into therapeutic drug discovery and development will help us expand a growing pipeline of targeted biologic candidates,” said Robert Mabry, Head of Global Biologics Research at Takeda.

Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will license to Takeda its “Library of Libraries,” a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body. Together, the companies will work to discover, validate and optimize new antibody candidates. In return, Takeda will pay Twist annual technology licensing fees, as well as milestones and royalties for all compounds discovered from the Twist phage display libraries.

“We look forward to applying our unique ability to generate robust, diverse and cutting-edge libraries together with Takeda’s deep insight into therapeutic drug discovery and development to truly forge new frontiers in bringing personalized therapies to patients worldwide,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

About Twist Biopharma

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including diagnostics, therapeutics, industrial chemicals, agriculture and academic research. For more information visit www.twistbioscience.com and www.twistbiopharma.com.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Check Also

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) …